Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

PLUR

Pluri Inc

May 10 • 04:00PM ET

5.82

Dollar change -0.14
Percentage change -2.43	%

Healthcare • Biotechnology • Israel • NASD

Stock Detail • Compare Perf. • Revenue • Options Chain • Save to Portfolio • Create Alert

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-4.17	Insider Own	24.56%	Shs Outstand	5.16M	Perf Week	1.13%
Market Cap	31.34M	Forward P/E	-	EPS next Y	-2.64	Insider Trans	0.00%	Shs Float	4.07M	Perf Month	0.26%
Income	-21.62M	PEG	-	EPS next Q	-0.24	Inst Own	2.26%	Short Float	0.97%	Perf Quarter	-6.54%
Sales	0.34M	P/S	92.18	EPS this Y	-	Inst Trans	-83.63%	Short Ratio	1.41	Perf Half Y	15.38%
Book/sh	-0.07	P/B	-	EPS next Y	-	ROA	-46.68%	Short Interest	0.04M	Perf Year	-12.42%
Cash/sh	4.88	P/C	1.19	EPS next 5Y	-	ROE	-231.11%	52W Range	3.45 - 8.56	Perf YTD	25.43%
Dividend Est.	-	P/FCF	-	EPS past 5Y	20.93%	ROI	-74.41%	52W High	-32.07%	Beta	1.62
Dividend TTM	-	Quick Ratio	6.05	Sales past 5Y	-25.35%	Gross Margin	18.48%	52W Low	68.61%	ATR (14)	0.45
Dividend Ex-Date	-	Current Ratio	6.05	EPS Y/Y TTM	42.14%	Oper. Margin	-6647.51%	RSI (14)	51.71	Volatility	4.70% 7.42%
Employees	134	Debt/Eq	-	Sales Y/Y TTM	93.75%	Profit Margin	-6339.59%	Recom	3.00	Target Price	24.00
Option/Short	No / Yes	LT Debt/Eq	-	EPS Q/Q	33.60%	Payout	-	Rel Volume	0.13	Prev Close	5.96
Sales Surprise	-	EPS Surprise	-	Sales Q/Q	-18.39%	Earnings	-	Avg Volume	27.96K	Price	5.82
SMA20	6.79%	SMA50	-7.84%	SMA200	8.85%	Trades		Volume	3,501	Change	-2.43%

May-02-24 07:00AM	Unleashing the Power of MAIT Cells: Pluri Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment (GlobeNewswire) +5.03%
Apr-08-24 07:00AM	Breakthrough in Immune Cell Expansion: Pluri Granted U.S Patent for New Method (GlobeNewswire)
Apr-03-24 02:52PM	PLUR Stock Earnings: Pluri Reported Results for Q4 2023 (InvestorPlace) -8.70%
Mar-28-24 07:15AM	Pluri's Business Verticals Gain Traction in Global Markets; Leadership to Participate and Present in Upcoming Conferences (GlobeNewswire) -8.39%
Mar-27-24 07:00AM	Pluri Inc. Announces 1-for-8 Reverse Share Split (GlobeNewswire) -13.75%
07:00AM	Loading…
Mar-21-24 07:00AM	Pluri's Sustainable Cell-Based Coffee Addresses Critical Challenges Revealed in International Coffee Organization Market Report (GlobeNewswire)
Mar-19-24 04:00AM	Engage with Pluri's Talent: Exciting Conference Appearances Ahead (GlobeNewswire)
Mar-14-24 07:00AM	Pluri Selected as CDMO by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing (GlobeNewswire)
Mar-11-24 07:00AM	Pluri Receives First-Ever Patent Approval for 3D Bioreactor Technology in Plant Cell Cultivation (GlobeNewswire)
Mar-06-24 07:00AM	Pluri Inc. Announces Appointment of Jim Roosevelt, Jr. to its Advisory Board (GlobeNewswire) +13.77%
Feb-28-24 07:00AM	Pluri's Innovation Across Various Industries: CEO Updates on Recent Achievements & 2024 Goals (GlobeNewswire)
Feb-12-24 05:20PM	Pluri: Fiscal Q2 Earnings Snapshot (Associated Press Finance)
Jan-23-24 02:00AM	Step into the Future: Pluri Launches Sustainable Cell-Based Coffee as Countermeasure for Global Coffee Crisis (GlobeNewswire) +15.81%
Jan-08-24 07:00AM	Pluri Launches Advanced Global Cell Therapy Contract Development and Manufacturing Organization (GlobeNewswire) -6.79%
Dec-21-23 07:00AM	Pluri and Bar-Ilan University to Develop PLX Cells for the Treatment of Cocaine Addiction (GlobeNewswire)
07:29PM	Loading…
Nov-13-23 07:29PM	Pluri: Fiscal Q1 Earnings Snapshot (Associated Press Finance) +5.99%
Aug-16-23 07:00AM	Pluris PLX-R18 Increases Blood Cell Counts and Reduces Need for Transfusions in a Phase I Study: Results Published in Nature Bone Marrow Transplantation (GlobeNewswire)
Jul-13-23 02:00AM	Pluri Announces Appointment of Entrepreneur Lorne Abony to Board of Directors (GlobeNewswire) +5.54%
Jul-12-23 11:17AM	Deutsche Bank Predicts up to 160% Rally for These 3 Stocks Heres Why They Have Solid Upside (TipRanks) -5.25%
Jul-11-23 02:00AM	U.S. National Institutes of Health to Fund $4.2 Million Contract to Advance Development of Pluris PLX-R18 in Conjunction with U.S. DoD as a Medical Countermeasure for Hematopoietic Acute Radiation Syndrome (GlobeNewswire) +8.91%
Apr-27-23 07:00AM	Cell Manufacturing Pioneer, Pluri Inc., Unveils PluriMatrix: a Breakthrough System for Unprecedented Industrial Scale Production of Cell-Based Products (GlobeNewswire)
Mar-13-23 08:00AM	Israels Ministry of Labor Names Pluri as Winner of the 2022 Egalitarian Employment Award for its Commitment to Gender Diversity and Pay Equity (GlobeNewswire)
Dec-22-22 07:00AM	Pluri CEO Issues Letter to Shareholders Summarizing the Strategy Change and Progress in 2022 and Announcing Food Tech Joint Venture Proof of Concept (GlobeNewswire)
Dec-15-22 04:05PM	Pluri Prices $8.2 million Private Placement Offerings Priced At-The-Market Under Nasdaq Rules (GlobeNewswire) +9.30%
Nov-10-22 07:00AM	Pluri wins BioTech Breakthrough Cell Innovation of the Year Award (GlobeNewswire) +8.10%
Oct-31-22 08:00AM	Pluri to Present and Participate in Upcoming Conferences (GlobeNewswire)
Sep-29-22 07:00AM	Pluri CEO Issues Letter to Shareholders Announcing New Tech Collaboration, Cost Reduction in line with New Strategy and Financial Updates (GlobeNewswire)
Sep-06-22 07:00AM	7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluris PLX-PAD Cells for Osteoarthritis Treatment (GlobeNewswire)
Apr-07-22 07:00AM	Plurilock's Aurora Systems Receives US$224,000 Purchase Order from the U.S. Library of Congress (Newsfile)
Apr-01-22 07:00AM	Plurilock Names Garr Stephenson Jr. as Chief Revenue Officer (Newsfile)
07:00AM	Loading…
Mar-31-22 07:00AM	Plurilock's Aurora Systems Receives US$1.5 Million Purchase Order from the U.S. Department of Defense (Newsfile)
Mar-28-22 07:00AM	Plurilock Submits Non-Provisional U.S. Patent Application for Multi-Device Identity Confirmation Technology (Newsfile)
Mar-23-22 07:00AM	Plurilock's Aurora Systems Receives US$1.85 Million Purchase Order from the U.S. Department of the Navy (Newsfile)
Mar-17-22 07:00AM	Plurilock Adds Brandon Swafford to Advisory Board (Newsfile)

Pluri, Inc. is a clinical stage company, which engages in cell therapy development. It develops placenta-based cell therapy product candidates for the treatment of multiple ischemic, inflammatory, and hematologic conditions. The firm focuses on the research, development, and manufacturing of cell-based products and technologies. Its products include Clinical Pipeline, PLX-Immune, PLX-PAD, and PLX-R18. The company was founded by Doron Shorrer on May 11, 2001 and is headquartered in Haifa, Israel.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

PLUR

Pluri Inc

Upgrade your FINVIZ experience